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Drug nanoparticles can achieve targeting capabilities, enhanced dissolution rates and 
improved bioavailability when injected intravenously. Sterile filtration of drug 
nanoparticle suspensions (nanosuspensions) is critically needed for administration by 
intravenous delivery route. Avoiding gamma irradiation and high temperatures, sterile 
filtration could be an effective process to sterilize drug nanosuspensions. On the other 
hand, two major challenges must be tackled: drug particles must at least be smaller than 
the filter pore size and minimum amount of non-toxic stabilizers must be used to prevent 
side effects like pain on the injection site. The aim of this study is to prepare naproxen 
(NPX) nanosuspensions via wet stirred media milling using various polymers and 
surfactants as stabilizers and to assess their physical stability with the ultimate goal of 
achieving the sterile filterability of such produced suspensions. An intensified milling 
process was investigated for fast production of sub-200 nm drug particles. In the second 
part, various formulations to stabilize NPX nanoparticles were screened. Lastly, the 
suspensions with NPX particle size less than 220 nm were filtered through a sterile 0.22 
μm disposable capsule filter.  Laser diffraction, scanning electron microscopy, rheometry, 
and surface tension measurement were used to evaluate the breakage kinetics and storage 
stability. Although NPX nanosuspensions were stabilized using stabilizers acceptable for 
injection, their sterile filtration was not successful, indicating a critical need for further 
research regarding the use of acceptable stabilizers and filter type/processing. 
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CHAPTER 1  
INTRODUCTION 
1.1 Objectives 
The goal of this exploratory and preliminary study is to assess the sterile filterability of 
Biopharmaceutical Classification System (BCS) Class II drug nanosuspensions, which 
are prepared via wet stirred media milling (WSMM). To achieve this goal, the thesis has 
the following specific objectives: (a) to explore the impact of process parameters on the 
final product nanosuspensions, (b) to study the impact of various stabilizers, i.e., 
polymers and surfactants, to impart physical stability against aggregation of drug 
nanoparticles present in the milled aqueous suspension, and (c) to filter the drug 
nanosuspensions which have D90 less than 220 nm through a sterile vacuum filter using 
four different membranes. 
1.2 Background Information 
1.2.1 Bioavailability Enhancement of Poorly Water-Soluble Drugs 
The bioavailability enhancement of BCS Class II (poorly water soluble) drugs can be 
achieved by (a) increasing the surface area of drug crystals by particle size reduction 
(Noyes and Whitney, 1897); (b) use of pro-drug and drug derivatives such as strong 
electrolyte salt forms that usually have higher rate of dissolution (Liu et al. 2006); (c) 
microemulsions which have been employed along with incorporation of proteins to 
increase solubility of drugs (Ashwini et al. 2014); (d) micellar solubilization, which 
involves use of surfactants to lower surface tension and improve the dissolution 




drugs, which has been used to enhance aqueous solubility and drug stability (Meyer et al. 
1998); (f) decreasing crystallinity of drug substance through formation of solid 
solutions/amorphous solids (Kim et al. 2008, Shen et al. 2010, Zhang et al. 2006); and (g) 
formation of water-soluble complexes (Jansook et al. 2010). 
1.2.2 Methods for Producing Drug Nanosuspensions 
Among various methods for enhancing the bioavailability of BCS Class II drugs, size 
reduction of the drug crystals to the nanometer scale has been identified to be a promising 
approach (Kondo et al. 1993, Liversidge et al. 1996). According to the Nernst–Brunner 
equation, particle size reduction increases the specific surface area enhancing the 
dissolution rate, which in turn improves the bioavailability of poorly water-soluble BCS 
class II drugs (Noyes and Whitney, 1897, A. Dokoumetzidis et al. 2006). As smaller 
particles dissolve faster, it is expected that drug nanoparticles with very large surface area 
could significantly enhance the dissolution rate, thus allowing for sufficiently high 
bioavailability for some of the BCS Class II drugs. 
There has been a growing interest in the production of drug particles in the size 
range 50-200 nm in a reproducible manner (Niwa et al. 2011, Juhnke et al. 2010). The 
manufacturing of a drug nanosuspension leads to the formation of nanoparticles with 
higher surface area and interface (Eerdenbrugh et al. 2008). Preparation of 
nanosuspensions involves adoption of two general approaches: bottom-up approach 
(forming nanoparticles from molecules) and top-down approach (size reduction). The 
best example of a bottom-up approach is anti-solvent precipitation/crystallization (Sinha 




precipitating the drug (the solvent known as non-solvent), which further controls the 
crystallization of drugs by presence of certain stabilizers in the non-solvent phase (Thorat 
et al. 2013). Due to the constraints in the bottom-up approach during scale-up, the top-
down approach has been commonly used as a promising technique for producing 
nanosuspensions (Ghosh et al. 2011). In the top-down approach, various wet milling 
techniques such as media milling, high-pressure homogenization (HPH), etc. have been 
used. Among these techniques, size reduction of drug crystals to a nanometer scale via 
wet stirred media milling has been determined to be a promising approach to boost 
bioavailability (Kondo et al. 1993, Liversidge et al. 1996). Typically, 100–500 nm 
particles were prepared by several hours of milling with relatively high-energy 
consumption (Bose et al. 2012, Cerdeira et al. 2010, Knieke et al. 2013). The process of 
media milling consists of mechanical attrition of drug particles using milling media such 
as yttrium stabilized zirconium oxide beads of definite size range (Van Eerdenburgh et al. 
2008). High-pressure homogenization has also been used because of its reduced product 
contamination (Keck and Muller, 2006). The mean particle size of nanosuspensions 
prepared by HPH is usually between 400 nm and 1000 nm (Lou et al. 2011, Wang et al. 
2011, Xiong et al. 2008).  
Wet stirred media milling (WSMM) has proved to be a robust top-down approach 
for producing nanosuspensions of poorly water-soluble drugs (Bhakay et al. 2011, Bruno 
et al.1996, Merisko-Liversidge et al. 2003) due to its universal applicability to all BCS 
Class II drugs, solvent-free/environmentally benign operation, capability to handle high 
drug loading, and scalability (Afolabi et al. 2014). Unlike other milling methods, WSMM 




pharmaceutical industry (Sinha et al. 2013). A cursory review of recent literature, which 
is not intended to be comprehensive, on finely milled BCS Class II drugs via WSMM is 
presented in Table 1.1. The data support the commonly held notion that fast preparation 





Table 1.1  Recent Literature on Drug Nanosuspensions Prepared via Wet Stirred Media Milling (WSMM) 
aNot Reported. 
bVolume of water (ml) used in the suspension. 
cMass (mg) of the suspension. 
dDays of ball milling. 
Drug Drug 
Loading 
(% w/w)  
















Naproxen 5 12b 300 240 NR
a
 200 Bitterlich et al. 
2015 
Naproxen 10 400b 200 64 143 238 Monteiro et al. 
2013 




 207 Sumit et al. 2014 
Naproxen 5 NR
a
 200 60 NR
a
 <500  George et al. 2013 
Iodipamide  15 1000 800-
1000 
5-10d 98 <220 Zheng et al. 1997 
Indomethacin 20 10 1000 21 NR
a





 30 200 2370 Sharma et al. 2009 
Fenofibrate 2.5 200 400 60 460 960 Knieke et al. 2013 
Naproxen 10 200 400 90 144 230 Sievens et al. 2012 
Griseofulvin  10 200 400 64 163 211 Bilgili et al. 2012 
6 
 
Wet stirred media milling (WSMM) involves the use of micron-sized drug 
particles and media (beads) in an aqueous solution of dissolved stabilizers usually 
polymers and/or surfactants, which are mixed by a stirrer (rotor) at a very high speed. 
The micron-sized drug particles are captured between the colliding beads due to repeated 
stressing caused by milling continued for adequate time. Production of nanosuspensions 
creates new interfaces resulting in positive Gibbs free energy. As a result, these 
nanosuspensions are thermodynamically unstable and undergo aggregation of particles, 
which leads to decrease in interfacial tension (Wu et al. 2011, Van Eerdenbrugh et al. 
2008). This problem can be dealt by wetting the hydrophobic surfaces of the drug 
particles on addition of stabilizers, which increases the activation energy of the 
aggregation process (Verma et al. 2009). Therefore, proper selection of stabilizers is 
mandatory. Stabilizers are added to prevent the aggregation of milled drug particles and 
to inhibit particle growth (ripening) during milling/storage. Dissolution and in vivo 
performance may be affected by aggregation of the milled drug particles, which can be 
prevented by addition of stabilizers (Ghosh et al. 2011, Kesisoglou et al. 2007). An 
optimal stabilizer type/concentration, which ensures proper short- and long-term physical 
stability of a drug nanoparticle suspension, is usually obtained by stabilizer screening 
studies at the bench-scale (Kesisoglou et al. 2007, Van Eerdenbrugh et al. 2008). 
Nanosuspensions are stabilized via steric and/or electrostatic mechanisms 
imparted by the use of various stabilizers. Steric stabilization is attained by adsorbing 
polymers onto the drug particle surface; whereas electrostatic stabilization is achieved by 
adsorbing charged molecules, both ionic surfactants and charged polymers, onto the 




contributed by both the physical properties of stabilizers and surface properties of the 
drug (Figure 1.1). The application of a proper stabilizer considers several factors:(a) 
polymer length and molecular weight of a polymer achieves a thermodynamic driving 
force for physical adsorption on the surface of the particle, (b) molecular weight of a 
polymeric stabilizer is inversely proportional to the rate of adsorption, (c) high 
concentration of long change polymers may lower the dissolution rate. Surfactants should 
be sparingly used in the pharmaceutical applications to lessen or diminish the unfavorable 
impacts: 
 Aggregation of drug nanoparticles in suspension during milling or storage above 
critical concentration (Cerdeira et al. 2010). 
 Micellar solubilization (Seedher et al. 2008), and size growth during Ostwald 
ripening (Knieke et al. 2013, Verma et al. 2011). 
 Toxicity (Liversidge et al. 2005) caused if used in excess especially in inhalation 
products (Lebhardt et al. 2011, Suzuki et al. 2000). 





Figure 1.1  The mechanism of stabilization of the milled drug particles during the media 
milling process.  
Source: George, M. & Ghosh, I. (2013), European Journal of Pharmaceutical Sciences 
1.2.3 Applications of Nanosuspensions in Intravenous Administration Route 
Nanosuspension is a carrier-free nanoparticle system containing only pure drug crystal 
and minimum surfactant and/or polymer dissolved in water for stabilization (Keck & 
Müller, 2006). Nanosuspension could greatly increase drug dissolution rate; this 
important feature renders it an excellent strategy to deal with BCS Class II and IV drugs 
(Müller et al. 2001, Rabinow, 2004, Kesisoglou et al., 2007). Routes of administration of 
drugs are generally classified as enteral and parenteral. Enteral route of administration 
deals with the GI tract and includes oral, buccal, and rectal route. Parenteral routes of 
drug delivery commonly refers to injectable such as intravenous (IV), intramuscular 
(IM), and subcutaneous (SC) but could also include topical and inhalation. Drug 
undergoes either first-pass metabolism or is not absorbed through the gastrointestinal 
tract in enteral route of administration. Consequently, the bioavailability after oral 




administration could provide greater bioavailability and is an alternative to oral 
administration (Xiong et al. 2008). All other categories of injections except IV must cross 
one membrane, involving an absorption process in the administration. As compared to 
other dosage forms, IV administration route offers many advantages: 
 Quick onset of action in case of emergency. 
 Reduction in dose of the drug and the ability to target the drug quickly to the 
desired site of action, especially in the case of severe infections. 
 Control over dose and rate allows more predictable pharmacokinetic profiles. 
 Control of plasma concentration. 
 Bioavailability is generally 100% as the whole dose is delivered to the blood 
stream. 
 Larger doses of poorly soluble drugs may be given in larger volume by IV 
infusion over an extended time. 
There is a considerable limitation in use of intravenous route due to harmful 
solvent and excipients, which can cause serious side effects other than the drug itself 
(Wang et al. 2011, Rabinow et al. 2007). Moreover, a prerequisite for the IV injection of 
suspensions is a small particle size, i.e. preferentially in the nanometer range with little 
content of microparticles (Muller et al. 1998). The microparticles lead to toxic effects and 
ultimately to emboli when they exceed a critical level in the administered dose (Davis 
and Traube, 1978, Schroeder et al. 1978, Slake et al. 1981). Thus, size range of ≤100 nm 
is preferred for parenteral nanocrystals (Jinno et al. 2006). Under such circumstances, 
nanocrystals could be considered as the ideal candidates for intravenous delivery 




1.2.4 Process Intensification 
Process intensification of WSMM process targets for faster production of particles below 
220 nm of BCS Class II drug particles. Drug particle sizes less than 220 nm may allow 
for successful sterile filtration. Despite previous experimental studies focusing on the 
impact of various process and formulation parameters on the milled particle size (Afolabi 
et al. 2014, Cerdeira et al. 2011, Ghosh et al. 2011, 2012, 2013, Monteiro et al. 2013, 
Singare et al. 2010, Singh et al. 2011), only Li et al. (2015) reduced milling time and 
energy consumption, while keeping media contamination low via intensification of 
process parameters such bead loading, rotor speed, and suspension flow rate upon use of 
optimal bead size.  
1.2.5 Sterilization of Drug Nanosuspensions  
Sterilization of drug nanosuspensions is critically intended for administration by 
intravenous injectables. This can be achieved by termination sterilization (e.g., 
autoclaving, sterile filtration, and gamma irradiation) of finished products or aseptic 
processing that is very costly. Autoclaving can lead to particle aggregation and thermal 
degradation of the drug due to use of high temperatures (Torchilin et al. 2006). Similarly, 
gamma irradiation can degrade the stabilizing polymers leading to particle aggregation 
and generate impurities along with the sterilization validation concerns (Torchilin et al. 
2006). Therefore, autoclaving and gamma irradiation are non-preferred processes for 
sterilization of drug nanosuspensions. While drug solutions can be sterilized commonly 
using the techniques mentioned here, only few drug nanosuspensions have been sterilized 
using these techniques, mainly the aseptic processing (Alekha et al. 2014). A platform 




does not exist. Hence, assessment of the sterile filtration of drug nanosuspensions is 
warranted, and is the goal of the present study. 
Filtration is aimed at sterilizing a drug solution or nanosuspension by removing 
microorganisms, which is followed by aseptic packaging. Unfortunately, drug 
suspensions pose a particular challenge: particles larger than the pore openings cannot 
pass through the filter and are retained on the surface of the filter (Grace H. P., 1956). An 
appropriate sterilizing grade filter is one that reproducibly removes all microorganisms 
from the process stream, producing a sterile effluent (Zheng et al.1997). Generally, 
capsule configurations of vacuum sterilizing grade filters, which are sterilized by gamma 
irradiation, are used. The total time for product filtration should be limited to established 
maximum to prevent microorganisms from penetrating the filter and to prevent a 
significant increase in upstream bioburden and endotoxin load (S. Niazi et al. 1949). 
Factors that can affect filter performance commonly include (a) viscosity of the material 
to be filtered, (b) pH, (c) compatibility of the material or formulation components with 
filter itself, (d) pressures, (e) flow rates, (f) maximum use time, (g) temperature, (h) 
osmolality, (i) and the effect of hydraulic shock (Jornitz et al. 2006). 
Most applications make use of filters made of cellulose esters, polyvinyl fluoride, 
polytetrafluoroethylene, nylon and other polymeric materials (Mckinnon et al. 1993). 
Membrane filters constitute of two types of membranes:  
 Hydrophobic (‘water-disliking’) for use with gas filtration, in which 




 Hydrophilic (‘water-liking’) for use with liquid filtration, in which compounds 
have affinity to water and are usually charged or have polar side groups to 
their structure that will attract water. 
The membrane filters must be fully compatible with the chemical characteristics 
of the nanosuspensions due to filter membranes containing non-toxic wetting agents that 
may interfere with some applications. Moreover, other membranes may bind proteins or 
other macromolecules, which may lead to premature filter clogging or loss of valuable 
samples. Therefore, it is very important to understand their characteristics and the 
potential effects filter membranes can have on the solutions they contact. The varying 
membranes used in sterile filters are as follows: 
 Cellulose Acetate (CA) membranes have low binding affinity, low chemical 
resistance, and are naturally hydrophobic. Furthermore, these membranes 
have small amounts (less than 1%) of non-toxic wetting agents to ensure 
proper wetting of the membrane (Corning Storage Bottles Selection and Use 
Guide). 
 Polyethersulfone (PES) membranes have faster flow rates. These membranes 
are without wetting agents and have low chemical resistance (Corning 
Filtration Guide). 
 Polyvinylidene fluoride (PVDF) membrane has high flow rates; ultra-low 
binding properties, and broad chemical and temperature resistance 




 Polyamide (PA) membrane is mechanically very strong and exhibits 
excellent wet strength and dry strength. Also, these are hydrophilic making 
them suitable for aqueous and organic solutions (Polyamide Membranes). 
1.3 Organization of Thesis 
Chapter 2 describes the experimental details of the study, including methods and 
materials for suspension and different filter membranes used, as well as methods for 
product characterization. Results and discussion of the impact of process parameters, 
different polymer and surfactant concentrations, different polymers and surfactants, and 
filtration studies are presented in Chapter 3. Chapter 4 presents a summative assessment 
of potential polymers and surfactants, stabilizing NPX nanosuspensions with an objective 




CHAPTER 2  
EXPERIMENTAL 
The methods of preparing and characterizing naproxen nanosuspensions are given in this 
chapter. Naproxen nanosuspensions were prepared via wet stirred media milling and their 
particle size, viscosity, and surface tension were characterized. The milled drug 
nanosuspensions with a final D90 particle size below 220 nm were sterile filtered using 
capsule filter with four different membrane materials. 
2.1 Preparation of Naproxen Nanosuspensions 
2.1.1 Materials 
WSMM experiments were carried out on the poorly water-soluble drug naproxen (NPX). 
Naproxen is a proprionic acid derivative related to the arylacetic acid group of 
nonsteroidal anti-inflammatory drugs (FDA). Figure 2.1 shows the chemical structure of 
NPX, which has a molecular weight of 230.26 Da and is practically insoluble in water. 
NPX is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic 
properties. Naproxen is rapidly and completely absorbed from the gastrointestinal tract 
with an in vivo bioavailability of 95%; hence, it serves as a model BCS Class II drug. 
 
 
Figure 2.1  Chemical structure of naproxen. 
Source: www.chemspider.com 




and therefore, they exhibit poor bioavailability resulting in multiple dosing of drug as 
well as fluctuation in blood concentrations (Medina et al. 2015). 
To stabilize the drug particles during milling and storage, different stabilizers 
were used in the suspensions. The physicochemical properties of different stabilizers are 
presented in Table 2.1  
Table 2.1  Properties of Stabilizers Used in Wet Stirred Media Milling
Stabilizers 
 
Solubility at 25 oC 
(mg/mL) 
Molecular weight  
(Da) 
Melting Point  
(oC) 
PVP 12 0.17 2000-3000 120 
PVP 17 0.17 7000-11000 126 
P188 >10% 7680-9510 52 
P407 >10% 9840-14600 56 
Tween 20 100 1225 56-58 
Tween 80 50-100 1310 -21 
HPC SL 20 100000 180-220 
SDS 150 288.38 206 
Soluplus  0.03 118000 166 






2.1.2 Preparation Methods 
Table 2.2 presents the suspension formulations used in this study. Feed NPX 
suspensions were prepared using a shear mixer (Cat#. 14-503, Fisher Scientific, 
Pittsburgh, PA, USA) running at a fixed speed of 300 rpm. To find an efficient process 
condition for fast production of drug particles, in Runs 1-3, HPC (SL grade)-SDS 
combination which provides sufficient stabilization for various drug nanoparticles 
such as griseofulvin, was selected based on our previous work (Bilgili & Afolabi, 
2012). Firstly, 2.5% HPC SL was added to deionized water in a beaker gradually for 
15 min while the mixer ran at a fixed speed of 300 rpm for 15 more min. Then, 0.5% 
SDS was added to the HPC SL solution gradually for 5 min and led to mix for 10 more 
min. All percentages (%) used throughout the preparation refer to w/w with respect to 
deionized water. The final HPC SL–SDS solution was further mixed for 15 min to 
ensure proper dissolution of HPC SL and SDS particles. For formulations wherein a 
single stabilizer was used (Runs 4-20), the stabilizer was added in 15 min and allowed 
to mix for another 15 min to ensure that the stabilizer is fully dissolved. Desired 
amount of NPX powder (10%) was weighed and added to the stabilizer solution 







Table 2.2  Stabilizer Percentages for Each Run in WSMM 
Run Stabilizer Concentration 
(% w/w)  
4 PVP 17 0.5 
5 PVP 17 2.5 
6 PVP 12 2.5 
7 PVP 17 5 
8 PVP 17 10 
9 HPC SL 2.5 
10 HPMC E3 2.5 
11 Soluplus 2.5 
12 P188 0.5 
13 P188 2.5 
14 P188 5 
15 P188 10 
16 P407 2.5 
17 Tween 20 2.5 
18 Tween 20 5 
19 Tween 80 2.5 





Figure 2.2  Schematic of the Netzsch stirred media mill (Model: Microcer) operating in 
the recirculation mode. P and T stand for Pressure Gauge and Thermocouple, 
respectively.  
Source: Bhakay, A., Davé, R., & Bilgili, E. (2013), Powder Technology. 
Drug suspensions were subsequently milled in a Netzsch wet media mill 
(Microcer, Fine Particle Technology LLC, and Exton, PA, USA). The wet stirred media 
milling process is depicted in Figure 2.2. The milling chamber is lined with zirconia and 
has a volume Vm of 80 ml. In this so-called recirculation mode, each feed suspension was 
poured into the holding tank and was recirculated between the holding tank and milling 
chamber at a constant volumetric flow by a peristaltic pump. The suspensions were 
milled for 64 min, which allowed sufficient time for preparation of NPX nanoparticles. 
Milling media (beads) are inside the milling chamber and set into motion by the rotation 
of the rotor. A turbulent motion was induced in the suspension by the high speed rotor, 
and turbulent energy dissipates during frequent bead–bead collisions (Eskin et al. 2005), 
causing extensive breakage of drug particles captured between the beads (Bhakay et al. 




were used as the milling media. A screen with 50 μm nominal opening size, located at the 
outlet of the milling chamber, retained the zirconia beads, while allowing the passage of 
the drug suspension. Both the milling chamber and the holding tank are equipped with a 
chiller unit (model number M1-25A-11HFX, Advantage Engineering, Green-wood, IN, 
USA) which kept the suspension temperature in the holding tank below 35°C, as a 
maximum. The stirrer was stopped occasionally followed by intermittent cooling when 
the temperature reached 35°C due to high heat generation rate. Samples were taken from 
the outlet of the milling chamber at several intervals of milling. The final suspensions 
(after 64 min milling) were tested for density and shear viscosity, and they were 
refrigerated at 8◦C for a period of 7 days. Particle sizes right after milling and after 7 days 
of storage were compared to assess the physical stability of the suspensions.  
Based on the process intensification approach proposed by Li et al. (2015), the 
process parameters were varied from the baseline (Run 1) first by reducing the bead size 
(Run 2) and then increasing the rotor tip speed, bead loading, and suspension flow rate 
simultaneously (Run 3), with the objective of achieving fast production of drug particles 
less than 200 nm in D90 (refer to Table 2.3 for the parameters).  The process parameters 
for Run 3, the intensified process, were then adapted for the rest of this study, where the 














1 3200 196 400 126 
2 3200 196 100 126 
3 4000 261 100 343 
 
 
Figure 2.3  Experimental set-ups for the sterile filtration process. 
2.2 Sterile Filtration of Nanosuspensions  
Filtration experiments of stabilized NPX nanosuspensions were performed at room 
temperature using polyvinylidene difluoride (PVDF), polyethersulfone (PES), cellulose 
acetate (CA), and polyamide (PA) vacuum membrane filters (Corning Incorporated Life 




membrane area of 19.6 cm2; and volume of 250 ml. A sterile filter is connected to the 
vacuum line and the nanosuspension was poured from the top on the filter membrane.  
30 g NPX nanosuspension was passed through sterile filters with four different 
membranes. All the drug particles larger than the surface opening or pore size are 
retained at or near its surface. 
 
Figure 2.4  Sterile vacuum filters used for sterile filtration of NPX nanosuspensions. 
Source: Innovative Products for Filtration and Ultrafiltration” Corning Filtration Guide. 
2.3 Characterizations 
2.3.1 Particle Size Distribution  
Particle size analysis of the milled suspensions was performed by laser diffraction using a 
Beckmann Coulter LS230. A polarized intensity differential scattering (PIDS) 
obscuration water optical model was employed. The PIDS was maintained between 40% 
and 50% while the obscuration was maintained 8% for all particle size measurements. A 
refractive index (RI) value of 1.61 for the NPX particles (Kean WF et al. 1989) and 1.33 
for the measurement medium (DI) water were used. Prior to the size measurement, milled 




suspension samples after 7-day storage were stored in room temperature for 30 min and 
then mixed via a digital vortex mixer (Thermo Fisher Scientific Inc., USA) at 1500 rpm 
for 1 min. ~2 ml samples were taken and diluted for particle size measurement using the 
same stabilizer solution as in the suspensions. Suspensions after filtration process were 
also tested for particle sizes immediately after filtration and after 7-day storage following 
the procedures above. 
2.3.2 Apparent Shear Viscosity 
The apparent shear viscosity of the milled suspensions was measured using an R/S plus 
rheometer (Brookfield Engineering, Middleboro, MA, USA) with a water jacket 
assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A coaxial cylinder (CC 
40) was used to impart controlled shear rate on the samples from 0 to 1000 1/s in 60 s. 
The temperature of the jacket was kept constant at 25 ± 0.2 oC. The raw data were 
analyzed using the Rheo 3000 software (Brook-field Engineering, Middleboro, MA, 
USA) of the R/S plus rheometer to obtain the apparent shear viscosity. 
2.3.3 Surface Tension 
The surface tension of the final HPC–SDS solution or HPC solution and milled 
suspensions was measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, 
USA). The Attention calculates surface tension from force measurements of interaction 




2.3.4 Scanning Electron Microscopy (SEM) 
Particle size and morphology of the as-received and milled drug particles were examined 
via SEM with a LEO 1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA). About 0.1 ml 
of the milled suspension was diluted with 30 ml de- ionized water, and a drop was placed 
on a silicon chip (Ted Pella, Inc., Redding, CA, USA), dried, sputter coated, and 
observed in SEM.  
2.3.5 X-Ray Power Diffraction (XRD) 
The crystallinity of the as-received drug, unmilled physical mixture (overnight dried 
aqueous suspension with as-received drug and PVP 17), and overnight dried, milled 
suspensions was analyzed using X-ray Powder Diffraction (XRD, PANalytical, West- 
borough, MA, USA), provided with Cu Kα radiation (λ = 1.5406 Å). The samples were 




CHAPTER 3  
RESULTS AND DISCUSSIONS 
3.1 Impact of Process Intensification 
3.1.1 Impact of Bead Size 
NPX particles were wet-milled using beads with two different nominal sizes: 400 and 
100 μm in Runs 1-2. Understanding the impact of bead size is crucial for subsequent 
process intensification of the most milling process (Li et al. 2015). 90% passing size (d90) 
obtained in Run 2 with 100 μm beads was 195 nm, which is slightly smaller than the one 
obtained in Run 1 with a particle size of 229 nm with 400 μm beads (Table 3.1). Smaller 
beads have higher frequency of bead-bead collisions and drug particle compressions 
despite potentially decreased maximum contact pressure (Li et al. 2015). Besides, wear of 
100 μm beads is expected to be lower than 400 μm beads, causing lower contamination in 
the milled drug suspensions (Li et al. 2015). Overall, it is suggested that the use of 100 
μm beads can be advantageous for the fast production of finer NPX particles and should 
be used for process intensification.  
3.1.2 Impact of Increase in Bead Loading, Rotor Speed, and Flow Rate 
Bead loading of 196 g was used in Runs 1-2, which produced a d90 of 195 nm in Run 2 at 
the lowest. The process was intensified in Run 3 with an increase in bead loading, rotor 
speed, and flow rate. The intensified milling condition was based on previous work Li et 
al. (2015). With the intensified process, drug particle size was reduced to 185 nm after 
milling, as shown in Table 3.1. Final particle sizes were approximately attained after 16 




smaller final particle size. There was a decrease in clearance between the beads upon 
increasing bead loading. The increase in rotor speed further led to a dramatic increase in 
the bead–bead collisions and drug particle compressions. When a higher suspension flow 
rate was used, the breakage rate was further increased due to tighter residence time 
distribution of the suspension in the mill chamber (Monteiro et al. 2012). The milling 
conditions in Run 3 led to the fastest NPX breakage and were therefore used in the 















400 µm, standard milling
100 µm, standard milling



















Figure 3.1  Impact of process parameters: (a) the time-wise variation of the median size, 
(b) the final particle size of NPX during milling. Runs 1, 2, and 3 refer to milling of NPX 
with 400, and 100 μm YSZ beads respectively at the baseline process conditions (Q = 
126 ml/min), and intensified process conditions (Q = 343 ml/min). At t = 0 min, NPX 
particles have d50 = 15.08 ± 0.15 μm and d90 = 37.59 ± 0.01 μm. 
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Table 3.1  Particle Size and Standard Deviation (SD) Obtained From Laser Diffraction 
(LD) for Runs 1-3 Suspensions After Milling and After 7 days Storage 
 
A rheological characterization of the milled suspensions was performed because 
the injectable formulations should have ideally low viscosity (preferably below 100 cP), 
yet being physically stable. Fig. 3.2 shows that all milled suspensions had less than 50 cP 
apparent shear viscosity, which is highly desirable for injectables. An addition of SDS to 
an HPC SL solution increased the viscosity significantly, which can be attributed to the 
formation of HPC–SDS aggregates or micelle-like SDS clusters bound to the polymer. 
Such HPC–SDS interactions are expected to result in a synergistic electrostatic 
stabilization (Bilgili and Afolabi, 2012). 
Run d50 ± SD (µm)  
After Milling 7-Day Storage 
d90 ± SD (µm)  
After Milling 7-Day Storage 
 1 0.124 ± 0.000 0.127 ± 0.001 0.229 ± 0.070 0.226 ± 0.007 
 2 0.122 ± 0.060 0.114 ± 0.002 0.195 ± 0.002 0.214 ± 0.015 
 3 0.110 ± 0.000 0.111 ± 0.001 0.185 ± 0.001 0.196 ± 0.005 
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The lowest apparent shear viscosity of 6.7 cP was obtained at 1000 (1/s) for Run 3 
in Table 3.2. The pre-suspension of 2.5% HPC SL and 0.5% SDS before milling showed 
the highest values of apparent shear viscosity of 162.7 cP at 1000 (1/s) shear rate. This 
and the ranking of Runs 1-3 suspensions (Table 3.2) can be explained by the fact that 
suspensions with smaller particle size exhibit lower viscosity. Similar observation was 
also made by Winnik and Winnik (1990), Evertsson and Nilsson (1997), and Berglund et 
al. (2003). Also, the viscosity of a milled suspension was lower than that of the stabilizer 
solution (Table 3.2) because of relatively well-dispersed nature of the NPX suspensions 
with HPC–SDS and the reduced concentration of HPC–SDS in the bulk solution of the 
NPX suspensions due to enhanced HPC SL adsorption (Bilgili et al. 2012). 
                        Shear rate (1/s)
100 1000
400 µm, standard Milling 
100 µm, standard Milling 
100 µm, intensified Milling 




























2.5% HPC SL, 0.5% SDS
             solution suspensions       
 
Figure 3.2  Log–log plots for apparent shear viscosity versus shear rate for (a) the HPC 




Table 3.2  Apparent Shear Viscosity of the HPC SL-SDS-based Solution and Suspensions 
at 25 °C and 1000 (1/s) Shear Rate  
Run Apparent Shear Viscosity (cP) 
Pre-suspension (unmilled) 162.7 





Table 3.3 shows that the HPC SL–SDS solution has higher surface tension than 
water (34.363 ± 0.111 mN/m) due to formation of micelle like SDS clusters bound to 
HPC SL. On the other hand, the surface tensions of milled suspensions were slightly 
lower than those of the corresponding stabilizer solutions because of the reduced bulk 
concentration of the stabilizers in the milled suspensions. HPC SL imparts poorer 
wettability to drugs in water relative to SDS even though it reduces surface tension of 
water (Dalvi et al. 2010, Rasenack et al. 2003).  
 
Table 3.3  Surface Tension for HPC SL-SDS Suspensions  
Run Solution (mN/m) 
Mean ± SD 
Milled Suspension (mN/m) 
Mean ± SD 
1 37.868 ± 0.064 34.363 ± 0.111 
2 37.786 ± 0.055 36.638 ± 0.377 





3.2 Impact of Polymer Concentration 
3.2.1 Particle Size of Milled Suspensions 
In the absence of any stabilizer, NPX particles alone could not be milled since it is 
very hydrophobic and a foam appeared during the milling and milling could not be 
continued. Thus, stabilizers are needed to reduce surface tensions and prevent 
aggregation. Figure 3.3 shows the evolution of the NPX particle size with different PVP 
concentrations during milling. HPC-SDS combination was used as a comparative 
baseline, which provides sufficient stabilization for NPX drug particles. However, HPC-
SDS combination cannot be used for injectables; hence, acceptable stabilizers like PVP 
are being investigated here. In general, NPX nanosuspensions were successfully prepared 
in the presence of PVP. The particle size decreased and attained a plateau in time; there 
was no significant increase in particle size during milling and storage (Table 3.4). Hence, 
PVP successfully suppressed the aggregation during the milling and storage. The effect 
of PVP concentration on particle size is relatively weak; the suspensions were stable even 
at low PVP concentration. A slight optimum concentration of 2.5% exists for PVP 17, in 
view of the 7-day stability data (Table 3.4), while 2.5% HPC SL in presence of SDS 
produced the lowest median size (d50) and 90% passing size (d90), i.e., 110 nm and 185 
nm respectively, due to synergistic stabilization imparted by HPC-SDS combination. 
Overall, these results suggest that stable NPX nanosuspensions can be prepared using 
polymers acceptable for injectable applications; however, the sterile filterability of such 













































Figure 3.3  Impact of polymer concentration: (a) the time-wise variation of the median 







Table 3.4  Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for NPX Suspensions After 
Milling and After 7 days Storage 
Run Formulation d50 (µm) ± SD d90 (µm) ± SD 
  After Milling 7-Day Storage After Milling 7-Day Storage 
3 2.5% HPC SL, 0.5% SDS 0.110 ± 0.000 0.111 ± 0.001 0.185± 0.001 0.196± 0.005 
4 0.5% PVP 17 0.124 ± 0.003 0.128 ± 0.000 0.215± 0.004 0.219± 0.000 
5 2.5% PVP 17 0.126 ± 0.002 0.130 ± 0.003 0.206± 0.000 0.209± 0.000 
7 5% PVP 17 0.135 ± 0.001  0.135 ± 0.001 0.212± 0.000 0.214± 0.001 
8 10% PVP 17 0.139 ± 0.001 0.139 ± 0.001 0.222± 0.000 0.225± 0.001 
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3.2.2 Apparent Shear Viscosity  
In order to investigate the impact of PVP 17 concentration on the suspension rheology, 
the apparent shear viscosity was obtained as a function of shear rate (Figure 3.4). HPC-
SDS was used as a baseline formulation to assess the performance of PVP at different 
concentrations. All of the polymer solutions and the milled NPX suspensions has 
apparent shear viscosity less than 6 cP at the maximum (Table 3.5), except the case of 
HPC-SDS solution. Low viscosity (below 100 cP, preferably 50 cP) is critical for 
injectable suspensions in mitigating the side effects and ensuring proper injections. The 









































2.5% HPC SL, 0.5% SDS
               solutions suspensions
 
Figure 3.4  Log–log plots for apparent shear viscosity versus shear rate for (a) the  




Table 3.5  Apparent Shear Viscosity of Different Concentrations of PVP 17 Suspensions 
at 25 °C and 1000 (1/s) Shear Rate  
 
3.2.3 Surface Tension   
In general, surface tension of the milled suspensions is higher than the stock solution for 
all PVP 17 concentrations, as shown in Table 3.6. The higher surface tension in the 
milled suspensions is probably due to the presence of a hydrophobic drug, absence of a 
surfactant, and PVP adsorption on drug particle surfaces, so that less amount of PVP is 
available in solution to reduce the suspension surface tension. Due to the presence of 
SDS, the solution and the suspension had similar surface tension values for NPX 
suspensions with HPC–SDS formulation, which had much lower surface tension than 
PVP formulation. 






3 2.5% HPC SL, 0.5% SDS 44.5 6.7 
4 0.5% PVP 17 3.6 4.9 
5 2.5% PVP 17 3.8 4.3 
7 5% PVP 17 4.1 4.4 
8 10% PVP 17 5.2 5.3 
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Table 3.6  Surface Tension for Different Concentrations of PVP 17 Suspensions 
 
3.3 Impact of Different Polymers 
3.3.1 Particle Size 
Impact of different polymers on the stabilization of NPX drug particles was studied in 
current section. The polymer concentration was fixed at 2.5% based on the optimized 
PVP concentration. HPC-SDS was again used as a baseline. The evolution of both D50 
and D90 exhibited a monotonic decrease for all polymers (Figure 3.5), except Soluplus. 
When Soluplus was used as a stabilizer, the drug particle size fluctuated during milling 
and the final particle size of D90 was above 1 µm. This suspension exhibited severe 
aggregation. The final particle sizes shown in Table 3.7 show that PVP 12, PVP 17, HPC 
SL, and HPMC E3 were all able to stabilize NPX nanoparticles without the use of a 
surfactant. On the other hand, only PVP 12 and PVP 17 grades were acceptable for 
injectable applications. 
 
Run Formulation Solution (mN/m) 
Mean ± SD 
Milled Suspension (mN/m) 
Mean ± SD 
3 2.5% HPC SL,  
0.5% SDS 
37.838 ± 0.090 36.517 ± 0.564 
4 0.5% PVP 17 47.763 ± 0.133 57.218 ± 0.213 
5 2.5% PVP 17 44.541 ± 0.115 52.027 ± 0.081 
7 5% PVP 17 51.933 ± 0.255 56.751 ± 0.216 















































Figure 3.5 Impact of different polymers on: (a) the time-wise variation of the median 












Table 3.7  Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for Different Polymer 
Suspensions After Milling and After 7 days Storage 
Run Formulation  d50 ± SD (µm) d90 ± SD (µm) 
  After Milling 7-Day Storage After Milling 7-Day Storage 
3 2.5% HPC SL, 
0.5% SDS 
0.110 ± 0.000 0.111 ± 0.001 0.185 ± 0.001 0.196 ± 0.005 
5 2.5% PVP 17 0.126 ±0.002 0.130 ± 0.003 0.206 ± 0.00 0.209 ± 0.000 
6 2.5% PVP 12 0.131 ±0.000 0.131 ±0.001 0.210 ± 0.001 0.213 ± 0.001 
9 2.5% HPC SL 0.135 ± 0.004 0.130 ± 0.000 0.201 ± 0.001 0.195 ± 0.001 
10 2.5% HPMC E3 0.135 ± 0.005 0.118 ±0.001 0.192 ± 0.001 0.189 ± 0.001 
11 2.5% SOLUPLUS 0.189 ± 0.020 0.135 ± 0.001 1.08 ± 0.756 0.213 ± 0.001 
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3.3.2 Apparent Shear Viscosity  
Viscosity measurement was conducted to all polymer solution and milled suspensions. 
All the polymer solutions and milled suspensions show viscosity less than 8 cP at the 
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Figure 3.6  Log–log plots for apparent shear viscosity versus shear rate for (a) the 







Table 3.8  Apparent Shear Viscosity of Different Polymer Suspensions at 25 °C and 
1000 (1/s) Shear Rate 






3 2.5% HPC SL, 0.5% 
SDS 
44.5 6.7 
5 2.5% PVP 17 3.8 4.3 
6 2.5% PVP 12 3.5 4.3 
9 2.5% HPC SL 7.6 4.9 
10 2.5% HPMC E3 6.3 7.3 
11 2.5% SOLUPLUS 3.7 4.9 
 
3.3.3 Surface Tension 
Table 3.9 shows that the surface tension of the milled suspension was higher than 
the stock solution, where polymer was used as the sole stabilizer. The increase in 
suspension surface tension is due to the polymers adsorption on drug particle surfaces, so 
that less amount of polymer is available in solution to reduce the suspension surface 
tension. In the cases of PVP 12 and PVP 17, it seems polymer with lower molecular 

















Table 3.9  Surface Tension for Different Polymer Suspensions 
Run Formulation Solution  
(mN/m) 
Mean ± SD 
Milled Suspension 
(mN/m) 
Mean ± SD 
3 2.5% HPC SL,  
0.5% SDS 
37.838 ± 0.090 36.517 ± 0.564 
5 2.5% PVP 17 44.540 ± 0.115 52.027 ± 0.081 
6 2.5% PVP 12 52.559 ± 0.854 57.567 ± 0.292 
9 2.5% HPC SL 42.227 ± 0.057 43.216 ± 0.088 
10 2.5% HPMC E3 41.902 ± 0.087  46.266 ± 0.138 
11 2.5% SOLUPLUS 43.231 ± 0.016  49.191 ± 0.366 
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3.4 Impact of Surfactant Concentration 
3.4.1 Particle Size 
This part of the study focuses on the impact of an injection-acceptable surfactant, i.e., 
Poloxamer concentration on NPX nanoparticle stabilization. HPC-SDS was again used as 
a baseline condition. Figure 3.7 shows that an optimum Poloxamer concentration exists to 
stabilize NPX nanoparticles, which is 2.5%. At 0.5%, severe aggregation took place, 
leading to the formation of coarse aggregates as large as 14 µm. Above 2.5%, an increase 
in Poloxamer concentration increased the final NPX particle size achieved (Table 3.10). 
However, all D90 values for the milled suspensions stabilized by Poloxamer were above 
0.3 µm (Table 3.10), suggesting that Poloxamer was not as effective as PVP in stabilizing 
the NPX particles. Particle sizes slightly increased after 7 days storage, especially for 
Poloxamer with the lowest concentration. Therefore, 2.5% was selected as an optimum 


















































Figure 3.7  Impact of surfactant concentration: (a) the time-wise variation of the median 









Table 3.10  Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for Surfactant Concentration 
After Milling and After 7 Days Storage 
Run Formulation d50 ± SD (µm) d90 ± SD (µm) 
  After Milling 7-Day Storage After Milling 7-Day Storage 
3 2.5% HPC SL, 
0.5% SDS 
0.110 ± 0.000 0.111 ± 0.001 0.185 ± 0.001 0.196±0.005 
12 0.5% P188 4.965 ± 5.422 6.251 ± 1.311 14.185 ± 5.017 18.487±0.815 
13 2.5% P188 0.169 ± 0.009 0.162 ± 0.003 0.324 ± 0.019 0.315±0.006 
14 5% P188 0.207 ± 0.085 0.248 ± 0.004 0.372 ± 0.038 0.398 ± 0.003 
15 10% P188 0.308 ± 0.014 0.312 ± 0.003 0.462 ± 0.031 0.475 ± 0.026 
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3.4.2 Apparent Shear Viscosity  
Viscosity measurement was conducted on all surfactant solutions and milled suspensions. 
All the surfactant solutions and milled suspensions show viscosity less than 7 cP at the 
maximum, except the case of HPC-SDS solution (Table 3.11). An increase in Poloxamer 
concentration increased the apparent shear viscosity in the presence or absence of the 
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Figure 3.8 Log–log plots for apparent shear viscosity versus shear rate for (a) the P188 
solutions; (b) milled NPX suspension
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Table 3.11 Apparent Shear Viscosity of Surfactant P188 Suspensions at 25 °C and 1000 
(1/s) Shear Rate  






3 2.5% HPC SL, 
0.5% SDS 
44.5 6.7 
12 0.5% P188 3.1 4.4 
13 2.5% P188 4.2 4.9 
14 5% P188 5.1 5.1 
15 10% P188 6.3 6.4 
3.4.3 Surface Tension  
Surface tensions of the milled suspension were higher than the stock solution in all the 
cases (Table 3.12), where Poloxamer was used as the sole stabilizer. The increase in 
suspension surface tension is due to the surfactant adsorption on drug particle surfaces, so 
that less amount of surfactant is available in solution to reduce the suspension surface 
tension. An increase in concentration of Poloxamer 188 consistently decreased the 
surface tension of the stabilizer solutions and milled suspensions.  
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Table 3.12 Surface Tension for Different Concentrations of P188 Suspensions 
3.5 Impact of Different Surfactants 
3.5.1 Particle Size 
The particle sizes in the nanosuspension for various injection-acceptable surfactants were 
plotted as a function of milling time as shown in Figure 3.9. While unacceptable for 
injection, HPC-SDS combination was used as a baseline formulation to stabilize NPX 
drug nanoparticle with a minimum amount of aggregates in the system. Two FDA 
approved injectable surfactants with two different molecular weights were investigated. 
All formulations with surfactant as the sole stabilizer showed monotonic decrease in 
particle sizes initially, followed by a light increase or decrease in D50 after 48 min. It is 
shown that Poloxamer 188 outshines other surfactants at 2.5%, but it is still not sterile 
filterable as it has a final particle size D90 above 220 nm (Table 3.13). The 7-day 
stability values demonstrated the particle size growth of NPX particles, which can be 
attributed to simple aggregation and possibly Ostwald ripening (Zu et al. 2014). Particle 
sizes after 7-day storage slightly increased, especially for Tween 20 and Tween 80.  
Run Formulation Solution (mN/m) 
Mean ± SD 
Milled Suspension (mN/m) 
Mean ± SD 
3 2.5% HPC SL, 
0.5% SDS 
37.838 ± 0.090 36.517 ± 0.564 
12 0.5% P188 44.344 ± 0.147 68.691 ± 2.727 
13 2.5% P188 44.524 ± 0.122 45.600 ± 0.131 
14 5% P188 42.563 ± 0.046 43.260 ± 0.218 






































Figure 3.9  Impact of different surfactants on: (a) the time-wise variation of the median 






Table 3.13  Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for Different Surfactants After 
Milling and After 7 Days Storage 
 
Run Formulation d50 ± SD (µm) d90 ± SD (µm) 
After milling 7-Day storage After milling 7-Day storage 
3 2.5% HPC SL, 
0.5% SDS 
0.110 ± 0.000 0.111 ± 0.001 0.185 ± 0.001 0.196 ± 0.005 
13 2.5% P188 0.169 ± 0.009 0.162 ± 0.003 0.324 ± 0.019 0.315 ± 0.006 
16 2.5% P407 0.275 ± 0.005 0.292 ± 0.006 0.417 ± 0.000 0.431 ± 0.001 
17 2.5% Tween 20 0.342 ± 0.009 0.364 ± 0.004 0.499 ± 0.025 0.537 ± 0.007 






3.5.2 Apparent Shear Viscosity  
Viscosity measurement was conducted on all surfactant solutions and milled suspensions. 
All the surfactant solutions and milled suspensions show viscosity less than 7 cP at the 
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Figure 3.10  Log–log plots for apparent shear viscosity versus shear rate for (a) different 












Table 3.14  Apparent Shear Viscosity of Different Surfactant Suspensions at 25°C and 
1000 (1/s) Shear Rate 
 
3.5.3 Surface Tension 
Surface tensions of the milled suspension were higher than the stock solution in all the 
cases (Table 3.15). The increase in suspension surface tension is due to the surfactant 
adsorption on drug particle surfaces, so that less surfactant is available in solution to 
reduce the surface tension. Tween was more effective than Poloxamers in reducing the 
surface tension.  






 3 2.5% HPC SL, 
0.5% SDS 
44.4 6.7 
13 2.5% P188 4.2 4.9 
16 2.5% P407 4.4 4.5 
17 2.5% Tween 20 3.4 3.6 






Table 3.15  Surface Tension for Different Surfactant Suspensions. 
Run Formulation Solution (mN/m) 
Mean ± SD 
Milled Suspension (mN/m) 
Mean ± SD 
3 2.5% HPC SL, 
0.5% SDS 
37.838 ± 0.090 36.517 ± 0.564 
13 2.5% P188 44.524 ± 0.122 45.6 ± 0.131 
16 2.5% P407 37.539 ± 0.028 37.938 ± 0.059 
17 2.5% Tween 20 35.554 ± 0.273 35.132 ± 0.262 
19 2.5% Tween 80 34.891 ± 0.442 34.58 ± 0.665 
3.6 Sterile Filtration 
Several stabilizers were identified to produce NPX nanoparticles less than 220 nm in D90. 
The feasibility of sterile filtration was assessed here. Four membranes, cellulose acetate 
(CA), polyethersulfone (PES), polyvinylidene fluoride (PVDF), and polyamide (PA) 
were tested. The comparison of filtration results with four membranes is given in Table 
3.16. For sterile-filterable suspensions, no significant change in particle size in the filtrate 
vs. 7-day stored suspension was observed after filtration. For example, 2.5% HPC SL- 
0.5% SDS formulation, which is a baseline formulation, is sterile filterable; however 
HPC SL and SDS are not admissible by FDA (US Food and Drug Administration) for 
injectable formulations. Therefore, this formulation cannot be used in intravenous 
injectables. On the other hand, the highly versatile polyvinylpyrrolidone PVP 17 is 
pharmaceutically acceptable by FDA and has diverse properties including its solubility in 
water and in a broad range of liquid media, high chemical and thermal resistance, and 
unique wetting, binding, and film-forming properties. Interestingly, the NPX 
nanosuspension with 2.5% PVP 17 cannot be filtered; drug particles could not pass 
through the membrane despite the fact that the nanosuspension had a D90 below 220 nm. 
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Considering the failure of 2.5% PVP 17 to prove its sterile filterability, 0.5% SDS as a 
favorable surfactant, was added to the same formulation for the filtration studies. 
However, even a combination of 2.5% PVP 17-0.5% SDS could not allow passage of the 
NPX nanoparticles through any of the membranes. NPX nanopaticles with HPC SL alone 
could be sterile filtered through only two membranes (PES and PVDF). Such failures 
have also been observed in previous literature because of various limitations listed below: 
 The particles of the membrane filters approximate the pore size of the filter 
surface because of their surface-retention mechanism. Such particles stop up the 
pores and prevent fluid flow (S.S. Block, 2001). 
 Not all the particles smaller than its pore size pass through the membrane filter. 
Some of these particles are collected on the membrane surface, and some are 
trapped in the tortuous capillaries themselves. If there are a sufficient number of 







Table 3.16  Filtration Studies in Different Membranes for: a) 2.5% HPC SL-0.5% SDS, b) 2.5% K17, c) 2.5% HPC SL 
Membrane 
(0.22 μm) 
d50 ± SD (µm) d90 ± SD (µm) 
 After Filtration 7-Day Storage After Filtration 7-Day Storage 
a) 2.5% HPC SL-0.5% SDS 
Cellulose Acetate 
(CA) 
0.105 ± 0.001 0.107± 0.001 0.175 ± 0.002 0.177 ± 0.001 
Polyethersulfone 
(PES) 
0.116 ± 0.002 
 
0.111 ± 0.002 0.177 ± 0.001 0.18 ± 0.002 
Polyvinylidene 
fluoride (PVDF) 
0.106 ± 0.001 0.107 ± 0.001 
 
0.175 ± 0.001 0.177 ± 0.001 
Polyamide (PA) 0.104 ± 0.003 0.108 ± 0.003 0.175 ± 0.001 0.176 ± 0 
b) 2.5% K17 
Cellulose Acetate 
(CA) 
NF NF NF NF 
Polyethersulfone 
(PES) 
NF NF NF NF 
Polyvinylidene 
fluoride (PVDF) 
NF NF NF NF 
Polyamide (PA) NF NF NF NF 
c) 2.5% HPC SL     
Cellulose Acetate 
(CA) 
NF NF NF NF 
Polyethersulfone 
(PES) 
0.131 ± 0.000 0.133 ± 0.001 0.190 ± 0.000 0.190 ± 0.000 
Polyvinylidene 
fluoride (PVDF) 
0.128 ± 0.003 0.135 ± 0.001 0.192 ± 0.001 0.192 ± 0.001 








Figure 3.11 shows the SEM image of as-received NPX particles and NPX 
particles after milling (Run 5). SEM images of the unmilled and milled NPX particles 
confirm the breakage of the NPX particles and formation of 50–250 nm primary particles. 
NPX particles become smaller and more rounded upon milling. A comparison of particles 
sizes based on laser diffraction measurement and SEM images suggests that NPX 
nanoparticles were formed by breakage, but they aggregated to various extents in the 
suspensions depending on the stabilizer used. Stabilizers allow proper wetting of the 
hydrophobic drug surfaces, which can help to disperse aggregates formed during the 
milling process (Kissa et al. 1999). Hence, both the laser diffraction and the SEM 
imaging suggest that the PVP 17 stabilized suspension had relatively small extent of 










Figure 3.11  SEM images showing the evolution of NPX particle size and morphology 
during Run 5: (a) as received (b) After 64 min milling. Run 5 refer to the use of 100 μm 
YSZ beads at the intensified process conditions (tip speed: 11.7 m/s, and flow rate: 343 
ml/min). Initially, the NPX particles have d50 = 14.645 ± 0.465 μm and d90 = 31.868 ± 




One concern for the wet media milling process is that the energetic process may 
lead to transition in the crystalline state of drugs. Figure 3.12 presents the XRD 
diffractograms of as-received NPX, physical mixture of NPX and 2.5% PVP 17, as well 
as milled suspension of NPX and 2.5% PVP 17 after overnight drying. The characteristic 
peaks of NPX appeared in all diffractograms without a broad halo after milling. As 
compared to the as-received NPX pattern, a slight reduction in the NPX peak intensities 
in the unmilled physical mixture is seen, which is due to dilution and surface coverage of 
NPX particles by PVP 17. On comparing dried, milled suspension’s pattern with that of 
the physical mixture, we note that the peak positions remained the same despite a 
reduction in peak heights after milling, which can be attributed to defect formation and 
accumulation during milling as well as the aforementioned dilution effect (Monteiro et al. 
2013). While XRD cannot detect minor amount of amorphous phase due to indirect 
inference, crystal orientation effects, and instrument-related intensity variations 
(Venkatesh et al. 2001), the aforementioned XRD results overall suffice to show that the 



















milled NPX suspension after drying
 
Figure 3.12  XRD diffractograms of as-received NPX, and unmilled physical mixture 
(NPX and 2.5% PVP 17), and dried, milled suspensions prepared with 100 μm YSZ 




CHAPTER 4  
SUMMARY AND CONCLUSION 
 
Naproxen (NPX) suspensions with various stabilizers have been produced via wet stirred 
media milling with the goal of achieving sterile-filterable drug nanosuspensions. Process 
intensification with smaller beads led to formation of NPX nanoparticles faster. The 
intensified process was then used to assess the impact of various stabilizers on the 
aggregation and physical stability. A baseline stabilizer formulation, HPC-SDS, was used 
as a baseline comparison, which led to D90 below 220 nm although it cannot be used for 
injectables. While HPC, HPMC, and PVP were more effective than various surfactants in 
stabilizing the NPX nanosuspensions, only PVP is acceptable for injectable application 
by FDA. Severe aggregation was observed when injection-acceptable surfactants were 
used especially at low concentration. The rheological characterization of the milled NPX 
suspensions suggests that most milled suspensions had relatively low viscosity (less than 
10 cP), which is highly desirable for injectables. The NPX nanosuspensions with D90 
below 220 nm were filtered through four different types of membranes. The concept of 
sterile filtration has been demonstrated with the HPC-SDS and HPC alone formulations; 
yet they cannot be used in injectable applications. While PVP allowed for NPX 
suspensions to have D90 below 220 nm, the respective nanosuspension cannot be sterile-
filtered through any of the membrane materials. Hence, we found that while D90 below 
220 nm is a necessary condition for sterile-filterability, but it is not sufficient. It is clear 
that NPX nanoparticles and PVP interact with membrane surfaces in such a way to cause 
blocking of the filters. Further research is required to understand such interactions toward 
designing a filter/process which ensures successful sterile filtration of nanosuspensions.
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CHAPTER 5  
FUTURE WORK 
 
The current study has dealt with various challenges to render NPX nanosuspensions 
sterile-filterable. The following topics or aspects are of major interest for future work: 
 A thorough literature search for identifying the FDA approved polymers–
surfactants and their concentration range 
 A thorough literature search for identifying the current and potential applications 
of sterile-filterable drug nanosuspensions such as long-acting parenteral 
suspensions 
 A thorough literature search for factors controlling the ultrafiltration process 
adopted in other chemical process industries 
 Combination of various polymers and surfactants to stabilize NPX 
nanosuspensions and assessment of the impact of this combination on sterile 
filterability 
 Use of multiple drugs to generalize the approach adopted in this study 
 Pre-filtration of the drug suspensions to remove coarse aggregates prior to sterile 
filtration with a 220 nm pore membrane filter 
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